**Early Notice of RFP Opportunities for Gavi Evaluations**

## **Gavi Mission**

To save children’s lives and protect people’s health by increasing access to immunisation in poor countries. Gavi, the Vaccine Alliance (“Gavi”) is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation, and other private sector partners. As part of its mission to save lives and protect people’s health by increasing equitable and sustainable use of vaccines, Gavi has helped vaccinate more than 981 million children in the world’s poorest countries, preventing more than 16.2 million future deaths. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology – from drones to biometrics – to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at [www.gavi.org](http://www.gavi.org).

## **Evaluation & Learning Unit role:**

The Centralised Evaluation Team (CET) within the Evaluation and Learning Unit at Gavi is responsible for the commissioning and day-to-day management of evaluations, including ensuring the utility, quality and timely delivery of evaluation reports and disseminating the findings.

The current pipeline of centralised evaluations to be commissioned **in *2023***is as follows:

Evaluation Title: **Phase 2 of the COVAX Facility and COVAX Advance Market Commitment (AMC) evaluation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| RFP publication | Background | High-level Objective | Anticipated Start Date | Anticipated End Date |
| April 2023 | Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator (which was launched in late April 2020.) This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines, and the COVAX Advance Market Commitment (AMC), a financing mechanism to ensure that low-income and lower middle-income economies, as well as other IDA-eligible economies have access to COVID-19 vaccines at the same time as wealthier economies. <https://www.gavi.org/covax-facility>  COVAX doses began to be shipped worldwide in late February 2021, and since then the partnership has delivered more than 1.8 billion doses to 146 countries.  In June 2022, the Gavi Board agreed that Gavi continue administrating the COVAX Facility in 2023. COVAX’s 2023 strategy will bridge to the Gavi 5.1 COVID-19 vaccine investment approach that would begin in 2024 and is focused on supporting AMC participants to meet their ambitions with a particular focus on expanding protection of higher priority population groups and in line with the evolving product and policy landscape. COVAX will also use 2023 to transition its operating model from one of leading an emergency response to a programme utilising established Alliance processes.  Gavi will commission this evaluation, to ensure the successes, challenges, and lessons learned from the COVAX Facility and COVAX AMC are independently evaluated and documented – both from a learning and an accountability perspective. | The purpose of this evaluation is to:   * Determine what was achieved through the COVAX Facility and COVAX AMC, including at country level, to finalise the contribution analysis and endline; * Assess the effectiveness and performance of the COVAX Facility (and to some extent the COVAX AMC); and * Generate lessons to inform future Gavi strategy.   This phase of the evaluation will focus on the period January 2022 through December 2023, and also leverage Phase 1 of this multi-stage evaluation covering up to December 2021[[1]](#footnote-2), to adequately respond to the evaluation questions across the lifespan of the COVAX Facility and COVAX AMC (July 2020 through December 2023). | Q3 2023 | Q2 2025 |

1. Final Evaluation Report to be completed in March 2023. [↑](#footnote-ref-2)